Teva takes HSBC loan to cover Protonix costs

Teva has taken a loan of several hundred million dollars to pay the patent infringement settlement it agreed with Pfizer and Takeda.

Sources inform "Globes" that Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has taken a loan of several hundred million dollars from UK bank HSBC Holdings plc (LSE: HSBA) in order to pay the $560 million it owes Pfizer Inc. (NYSE: PFE; LSE: PFZ) and Japan's Takeda Pharmaceutical Co. Ltd. (TSE: 4502) to settle the patent infringement suit over its 2007 "at risk" launch of generic version of Protonix.

Teva said, "Teva does not comment on information regarding its relations with banks except that which is published for the public." HSBC declined to comment.

Teva has been assisted by HSBC in several of its financing procedures in recent years. For example in 2011, HSBC and Citibank provided a $1.5 billion credit line for the pharmaceutical company and later served as one of the underwriters in Teva's bond offering on Wall Street. Following the acquisition of Cephalon that same year, HSBC extended an additional credit line and served as underwriter in a further large bond offering.

In the Protonix settlement, Teva agreed to pay Pfizer and Takeda $1.6 billion - half this year and the $800 million balance by October 2014. In recent quarterly results Teva has already recognized sums set aside for the settlement.

Although Teva believes it is entitled to insurance coverage from the Illinois Union Insurance Co. for some of the compensation, the insurance company itself insists it does not need to pay out. Teva has not reported any legal proceedings related to the matter.

Published by Globes [online], Israel business news - - on September 30, 2013

© Copyright of Globes Publisher Itonut (1983) Ltd. 2013

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2016